MDXXF (Pharmala Biotech Holdings) Institutional Ownership: 3.61% (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.14
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Institutional Ownership?

Pharmala Biotech Holdings MDXXF -1.43% 33 Institutional Ownership is 3.61% as of Aug. 17, 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharmala Biotech Holdings's institutional ownership is 3.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharmala Biotech Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharmala Biotech Holdings's Float Percentage Of Total Shares Outstanding is 0.00%.

Pharmala Biotech Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Institutional Ownership Chart

Pharmala Biotech Holdings Historical Data

The historical data trend for Pharmala Biotech Holdings can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31
Institutional Ownership 3.61 3.61 3.61 3.61 3.61 3.61 3.61 3.61 3.61 3.61
MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.61% mean?
Pharmala Biotech Holdings (MDXXF) has a Institutional Ownership of 3.61% as of Aug. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' Institutional Ownership too high?
Pharmala Biotech Holdings' current Institutional Ownership is 3.61%. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Institutional Ownership compare to VRTX and REGN?
Pharmala Biotech Holdings' Institutional Ownership of 3.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current Institutional Ownership is 3.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.14 — trading 19% below its estimated fair value. The current Institutional Ownership is 3.61%. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Institutional Ownership is 3.61% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.14 is trading 19% below its estimated GF Value™ of $0.17. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • Institutional Ownership: 3.61%
  • GF Value™: $0.17 vs. price of $0.14 (19% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$0.17
GF Value